BIOMAT Database Logo BIOMAT Database Logo

Drug monitoring and viral response to lopinavir/ritonavir or saquinavir/ritonavir containing regimens in individuals infected with the human immunodeficiency virus type 1. 2005

B Falkensammer, and W Fasser, and K Scherer, and A Zemann, and W Parson, and H Ulmer, and M P Dierich, and H Stoiber
Department of Hygiene, Microbiology and Social Medicine and Ludwig-Bolzmann-Institute for AIDS Research, Innsbruck Medical University, Austria. Barbabra.Falkensammer@uibk.ac.at

The aim of this study was to correlate results of therapeutic drug monitoring, genotypic resistance and viral response to lopinavir/ritonavir (LPV/r) or saquinavir/ritonavir (SQV/r) containing antiretroviral regimens. The retrospective short-term study included 20 patients with LPV/r and 20 patients with SQV/r containing highly active antiretroviral therapy (HAART). At baseline 7 LPV/r patients and 10 SQV/r patients had CD4+T cell counts above 410 cells/microl. After 6 months CD4+T cells had doubled in 5 LPV/r and 2 SQV/r patients. In LPV/r patients the mean serum concentration of lopinavir (LPV) was 2.6 ppm and 67% of all LPV/r samples had 50 or fewer viral copies/ml. In SQV/r patients the mean serum concentration of saquinavir (SQV) was 2.1 ppm. 79% of all SQV/r samples had 50 or fewer viruses/ml. Pharmacoenhanced regimens efficiently suppress human immunodeficiency virus type 1 (HIV-1) and the risk of developing resistance mutations is therefore reduced. The implementation of drug monitoring is an additional tool to determine optimal treatment conditions.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011744 Pyrimidinones Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O. Pyrimidinone,Pyrimidone,Pyrimidones
D005260 Female Females
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D015483 HIV Antibodies Antibodies reactive with HIV ANTIGENS. AIDS Antibodies,HIV-Associated Antibodies,HTLV-III Antibodies,HTLV-III-LAV Antibodies,LAV Antibodies,Lymphadenopathy-Associated Antibodies,T-Lymphotropic Virus Type III Antibodies, Human,HIV Associated Antibodies,HTLV III Antibodies,HTLV III LAV Antibodies,Lymphadenopathy Associated Antibodies,T Lymphotropic Virus Type III Antibodies, Human,Antibodies, AIDS,Antibodies, HIV,Antibodies, HIV Associated,Antibodies, HIV-Associated,Antibodies, HTLV III,Antibodies, HTLV-III,Antibodies, HTLV-III-LAV,Antibodies, LAV,Antibodies, Lymphadenopathy Associated,Antibodies, Lymphadenopathy-Associated

Related Publications

B Falkensammer, and W Fasser, and K Scherer, and A Zemann, and W Parson, and H Ulmer, and M P Dierich, and H Stoiber
[Lopinavir/ritonavir in human immunodeficiency virus-infected women].
November 2014, Enfermedades infecciosas y microbiologia clinica,
B Falkensammer, and W Fasser, and K Scherer, and A Zemann, and W Parson, and H Ulmer, and M P Dierich, and H Stoiber
Comparison of ritonavir plus saquinavir- and nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency type 1 infection.
January 2000, The Pediatric infectious disease journal,
B Falkensammer, and W Fasser, and K Scherer, and A Zemann, and W Parson, and H Ulmer, and M P Dierich, and H Stoiber
Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.
September 2003, The Journal of infectious diseases,
B Falkensammer, and W Fasser, and K Scherer, and A Zemann, and W Parson, and H Ulmer, and M P Dierich, and H Stoiber
Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children.
October 2004, The Pediatric infectious disease journal,
B Falkensammer, and W Fasser, and K Scherer, and A Zemann, and W Parson, and H Ulmer, and M P Dierich, and H Stoiber
Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.
December 2001, Antimicrobial agents and chemotherapy,
B Falkensammer, and W Fasser, and K Scherer, and A Zemann, and W Parson, and H Ulmer, and M P Dierich, and H Stoiber
Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants.
June 2007, Antimicrobial agents and chemotherapy,
B Falkensammer, and W Fasser, and K Scherer, and A Zemann, and W Parson, and H Ulmer, and M P Dierich, and H Stoiber
Similar efficacy of lopinavir/ritonavir-containing regimens among clades B and F HIV-1-Infected individuals in Brazil.
March 2008, Journal of acquired immune deficiency syndromes (1999),
B Falkensammer, and W Fasser, and K Scherer, and A Zemann, and W Parson, and H Ulmer, and M P Dierich, and H Stoiber
Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.
September 2002, Antimicrobial agents and chemotherapy,
B Falkensammer, and W Fasser, and K Scherer, and A Zemann, and W Parson, and H Ulmer, and M P Dierich, and H Stoiber
Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.
December 2008, The Journal of antimicrobial chemotherapy,
B Falkensammer, and W Fasser, and K Scherer, and A Zemann, and W Parson, and H Ulmer, and M P Dierich, and H Stoiber
Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.
June 2009, AIDS (London, England),
Copied contents to your clipboard!